Pathological diagnosis of follicular variant of papillary thyroid carcinoma has high inter and intra-observer variability among expert pathologists, aff ecting prognosis and management of the disease. A recent study applying strict diagnostic criteria and long-term follow up confi rmed the indolent behavior of a subtype of these tumors. They recommended a nomenclature change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features, refl ecting the low risk of adverse outcomes. We searched the pathology archives of King Abdulaziz University Hospital from 2002-2016 for all cases diagnosed with "follicular variant of papillary thyroid carcinoma". Clinical data, and imaging fi ndings were retrospectively reviewed. Available pathology slides were reviewed using the proposed inclusion and exclusion diagnostic criteria. We confi rmed the diagnostic reproducibility of the suggested criteria. Ten out of 37 cases met the diagnostic criteria. Eight additional patients could have had their diagnosis modifi ed if suffi cient tissue samples were available. Follow up data confi rmed the indolent behavior in these cases with no recurrence or adverse outcome. We concluded that application of the new diagnostic criteria for this subtype is reasonable and has major ramifi cations for the diagnosis and management as this will spare unnecessary thyroidectomies, radioactive iodine therapy, and their complications.
Introduction
Multiple neoplasms of the thyroid gland exist, each with diff erent morphological features, prognosis, and management. Well-diff erentiated thyroid carcinomas fall into two main categories: Papillary thyroid cancer and follicular thyroid carcinoma. Diagnosis of each type depends on certain well-defi ned histopathological features. Papillary thyroid cancer is the most common type with a reported increase in incidence in the last decade [1] . Diff erent variants of papillary thyroid cancer exist with the follicular variant being most commonly diagnosed after the classical type [1] . The management of this variant was previously through total thyroidectomy, and sometimes followed by radioactive iodine ablation. Recently, 24 endocrine pathologists from 4 diff erent continents conducted a large, retrospective study regarding this entity. They reviewed cases of the follicular variant of papillary thyroid carcinoma (FVPTC) from diff erent institutes and applied strict inclusion and exclusion criteria. The selected cases were followed over a period of 10-26 years in an attempt to defi ne their prognosis. The study confi rmed the benign behavior of a subtype of this neoplasm and recommended a change in its nomenclature to one that refl ects its benign, indolent behavior: "Noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) [2] . In our study, we applied the recommended inclusion and exclusion criteria to cases from the archives of a tertiary care center in Saudi Arabia. Our aims were to determine the applicability of these pathological criteria, and to confi rm the benign behavior of these neoplasms in a diff erent population.
Methods
Approval from the Research Committee of the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz University was obtained prior to commencement of the study. We searched the archives of the pathology department covering the period 2002-2016 for all cases designated as "follicular variant of papillary thyroid carcinoma". We retrieved 37 cases. The clinical data (sex, age at onset and surgical intervention), imaging study, and pathological fi ndings were retrospectively reviewed. All patients were followed up until May 2016. The available pathological slides were reviewed and the diagnostic inclusion and exclusion criteria were adopted from the recently published article [2] . The diagnostic criteria were as follows: Encapsulated or clearly demarcated tumor with a follicular growth pattern and nuclear features of papillary thyroid carcinoma (PTC) (score 2 or 3). The nuclear features were scored as present (1) or absent (0) for the following characteristics: Size and shape (enlargement of the nuclei with overlapping, crowding and/or elongation); nuclear membrane irregularity (irregular nuclear contour, nuclear pseudoinclusion and grooves); chromatin characteristics (nuclear clearing with margination and glassy nuclei) (Fig. 1A, 1B) . The exclusion criteria were: Papillae formation in more than 1% of the tumor, the presence of psammoma bodies, an infi ltrative border (Fig. 1C, 1D) , and tumor necrosis, the presence of at least 3 mitoses per 10 highpower fi elds, and cell /morphologic characteristics of other variants of PTC (Fig. 1E, 1F ).
Results
We reviewed the 37 cases found in our archives. This included 34 female and 3 male patients. The age of patients ranged from 19 to 78 years at the time of diagnosis (median age, 37 years and mean age, 40 years. The tumor size ranged from 0.3 cm to 2.5 cm. Twentysix cases were excluded from the study after reviewing the available pathological slides and the reasons for exclusion are summarized in Table 1 . Eleven cases were found to meet the diagnostic criteria for the new entity; one case had no follow up data and was subsequently excluded. The fi nal number of cases included in this study was 10. A summary of the selected cases and their clinical data as well as follow up results are shown in Table 2 .
We found that application of the proposed diagnostic and exclusion criteria was simple, reasonable, and reproducible. A few cases were challenging and this was mainly related to the amount of tissue sampled from the neoplasm. The proposed criteria for adequate sampling of these neoplasms were not specifi ed; generally, assessment of the whole capsule is preferred. However, due to the well-known variation in the amount of sampling between pathologists, 8 cases in our small cohort were excluded as the sampling was considered inadequate for the diagnosis of this variant. Another major problem was dealing with multiple nodules with FVPTC features. In this scenario, only representative sections, and not the whole thyroid, were submitted for histological diagnosis. One case was associated with nodal metastasis.
Eight cases were managed initially by total thyroidectomy, one with initial lobectomy followed subsequently by complete thyroidectomy and Eff ect of Implementing the New Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm...
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radioactive iodine and one by lobectomy alone. All cases were followed up until May 2016 and none showed adverse events including metastasis or recurrence. This data supports the benign, indolent behavior of this thyroid neoplastic entity.
Discussion
Well-diff erentiated thyroid cancer includes 2 variants: Follicular carcinoma (FC) and papillary thyroid carcinoma [1] . The diagnosis of follicular carcinoma depends on detection of capsular and or vascular invasion [1] , while the diagnosis of papillary carcinoma depends on the presence of papillary formation and certain nuclear features (namely PTC-type nuclei) even in the absence of capsular and or vascular invasion [3] . The nuclear features include optically clear nuclei, nuclear grooves, overlapping, pseudoinclusions, enlargement, and irregularities of the nuclear contours.
The FVPTC is characterized by follicles lined by cells with PTC-type nuclei but with no papillae formation. The name of this entity was introduced by Lindsay in 1960 [4] and further delineated by Chen and Rosai in 1977 [5] . As it is a variant of PTC, nuclear features alone have been considered suffi cient to label this variant as malignant [5] even in the absence of capsular and or vascular invasion. The pathological diagnosis of this variant has suff ered from high inter-observer [6] [7] [8] and even intra-observer variability among experts in thyroid pathology [8] . Additionally, pathologists from many countries use diff erent thresholds, for example an American pathologist diagnosed PTC at a higher frequency compared to a Japanese pathologist [6] . As such, there has been controversy in the literature Eff ect of Implementing the New Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm...
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regarding diagnosis, treatment, and the behavior of this entity.
The major reason for the controversy regarding the pathological diagnosis was that diff erent expert pathologists have diff erent thresholds for accepting what nuclear features were suffi cient in a follicular lesion to call it FVPTC. This resulted in three possibilities for a follicular lesion with questionable PTC-nuclear features: First, the nuclear features were considered suffi cient and subsequently termed FVPTC and considered malignant. Second, the nuclear features were not suffi cient and subsequently the lesions were considered follicular neoplasms and if they demonstrated capsular and/or vascular invasion, they were considered malignant. The third was to accept the limitations and name these nuclear features as equivocal. The latter situation was approached by William, on behalf of the Chernobyl Pathologists Group, who proposed a diff erent terminology to deal with these cases [9] . The proposal was to admit to our limitations and the uncertainty of this group and to look for other features of malignancy (namely capsular and/or vascular invasion). If these were present, then the neoplasm would be called a well-diff erentiated carcinoma not otherwise specifi ed (WDC-NOS). While if they were absent, then the neoplasm would be termed a well-diff erentiated tumor of uncertain malignant potential (WDT-UMP) [9] . For the latter group, owing to their extremely good prognosis, they suggested that no further treatment is required. However, this proposition was not widely accepted among other experts in the fi eld [1] . The importance of concentrating on the capsule in FVPTC and to classify these tumors into encapsulated (invasive and non-invasive) and non-encapsulated was clearly demonstrated by Liu et al. [10] . In this study, 43 non-invasive encapsulated tumors had no evidence of recurrence or lymph node metastasis with a median follow-up of 10.8 years in contrast to the other groups (namely invasive encapsulated and the infi ltrative/ diff use non-encapsulated), which behaved like a classic papillary thyroid carcinoma [10] . In another approach to confi rm the favorable prognosis of this entity, Piana et al. [11] reviewed the follow up data of 1009 cases of thyroid carcinoma for an average of 11.9 years or until death. They selected 67 fatal cases and reviewed the pathological diagnosis. None of these cases were encapsulated FVPTC although there were 66 cases of FVPTC in the initial cohort [11] . However, this study was limited, as it did not distinguish between invasive and non-invasive cases.
Although FVPTC with capsular and/or vascular invasion behaves as a malignant neoplasm, the behavior of the remaining cases was unclear. One group should be termed "cancer" as they behave like conventional PTC, while the other behaves in a benign fashion. Due to the uncertain behavior of FVPTC with no capsular and/or vascular invasion, diff erent treatments have been off ered to patients. Institutions with an excellent follow up system and compliant patients may off er lobectomy with frequent follow up assessment, while others may decide to treat with these patients by complete thyroidectomy with or without radioactive iodine therapy. However, as a result of the recent study by Nikiforov et al. [2] and the consensus change by experts in the fi eld, these treatments may change.
With major advances in the diagnosis, it is clear that certain features apart from the presence of PTC-type nuclei are extremely important for these neoplasms and their indolent behavior. In order to maintain the classifi cation of this variant and its indolent behavior, the diagnostic and exclusion criteria must be strictly applied. In the current study, we found one of the major variables that aff ected diagnosis was the sampling adequacy. There is variability in what is accepted as "adequate" sampling between institutes and pathologists, especially when sampling thyroid neoplasms. This variation could be anywhere from the accepted general sampling rule for any neoplasm (at least 1 section / 1 cm) to sampling the whole thyroid. Although there is no minimum accepted adequate sampling for this diagnosis, assessment of the whole capsule is preferable for diagnosis of this variant. We excluded 8 cases from our small cohort as we considered them to be inadequately sampled to diagnose this specifi c variant. Another important issue was how to address multifocal NIFTP neoplasms. In our cohort, we found one case of multifocal NIFTP with nodal metastasis. Although the nodules that were sampled were done so adequately, not all the nodules were sampled and as such some of the smaller unsampled nodules may have had features of conventional PTC rather than NIFTP. Therefore, in patients with multifocal neoplasms, we recommend that either all nodules or the whole thyroid are sampled for the diagnosis of NIFTP (multifocal).
As this is the fi rst entity to be converted from "cancer' to neoplasm with benign behavior, it will have a huge impact on patients, their insurance, society, as well as the health care budget. It will also greatly infl uence our tertiary care center as 10 out 37 cases (27%) from our pathology archive will have to undergo a nomenclature change from the word "cancer" to "neoplasm". This number would have been higher if adequate sampling and good follow up data were available in all cases. These changes aff ect both the pathologist and treating clinician. For the pathologist, we cannot over-emphasize the importance of adequate sampling of thyroid neoplasms in order to diagnose this variant. As this is a newly introduced variant, clinicians who read the pathology report should be aware of this entity and may discuss cases with a diagnosis of FVPTC with the pathologist to include the possibility of NIFTP.
Conclusion
The application of the new well-defi ned diagnostic criteria for NIFTP is reasonable and reproducible. The application of these criteria to cases previously diagnosed as FVPTC may change the diagnosis from "cancer" to neoplasm with indolent behavior (NIFTP). A signifi cant number of patients would benefi t from this modifi cation both psychologically and in terms of their management, as this will spare unnecessary treatment such as thyroidectomies, radioactive iodine therapy and their complications. The major impact of this modifi cation to the nomenclature should be maintained by awareness of these changes and the strict application of inclusion and exclusion criteria for diagnosis.
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